Biagio Paolini

Dr. Biagio Paolini

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
MDMarcello Deraco
Marcello Deraco
ABAlessia Bertolotti
Alessia Bertolotti
GMGabriella Montemurro
Gabriella Montemurro
BPBiagio Paolini
Biagio Paolini
MPMarco A. Pierotti
Marco A. Pierotti
MCmaurizio VSS colecchia
maurizio VSS colecchia
The Sertoli cell tumor (SCT) of the testis is a sex cord stromal tumor, usually sporadic, rarely associated with genetic syndromes. Much remains unclear about the molecular genetic changes involved in SCT and its histogenesis. Recently, nuclear β-catenin immunostaining has been reported in a case of bilateral SCT, but the molecular basis of the aberrant nuclear β-catenin expression remains uncertain. In the present study, β-catenin immunohistochemical assay and mutational analysis of exon 3 of the CTNNB1 gene by direct sequencing were performed in 14 SCTs, 2 of which had an unfavorable clinical course. Immunohistochemical study showed that β-catenin was located in the cytoplasm of tumor cells in 4 cases (28.6%) and in both the nuclei and the cytoplasm in the remaining 10 cases (71.4%). β-Catenin mutations were detected in 10 of the 14 patients (71.4%) under evaluation. Ten of 10 mutation-carrying cases showed strong nuclear and diffuse cytoplasmic β-catenin immunoreactivity. Seven of the 8 CTNNB1-mutated tumors tested for cyclin D1 displayed diffuse immunoreactivity in the nuclei of tumor cells. We conclude that CTNNB1 exon 3 mutations are likely to be involved in the pathogenesis of male SCT with nuclear accumulation of β-catenin and affect the expression of cyclin D1.

1 June 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
GBGiorgio Bogani
Giorgio Bogani
AMAndrea Mariani
Andrea Mariani
BPBiagio Paolini
Biagio Paolini
ADAntonino Ditto
Antonino Ditto
FRFrancesco Raspagliesi
Francesco Raspagliesi

6 December 2010 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
MCmaurizio VSS colecchia
maurizio VSS colecchia
Andrea NecchiAndrea Necchi
Andrea Necchi
BPBiagio Paolini
Biagio Paolini
NNNicola Nicolai
Nicola Nicolai
RSRoberto Salvioni
Roberto Salvioni
Teratoma with a malignant somatic component (MSC) is a rare phenomenon recognized when a somatic type malignancy occurs in the context of a germ cell tumor (GCT). The authors present their 29-year experience with 40 patients treated from 1981 to 2009 in their institution. The average age was 31 years. All patients underwent radical orchiectomy, which demonstrated a GCT in 19 with an MSC. The MSC was observed in the other 21 cases in metastatic sites, including lung (13), liver (3), pleura (1), mediastinum (7), supraclavicular lymph nodes (1), and retroperitoneal lymph nodes (9). The most common histologic types were rhabdomyosarcoma (n = 11) and primitive neuroectodermal tumors (n = 10), followed by adenocarcinoma (n = 9), sarcoma, not otherwise specified (n = 5), well-differentiated liposarcoma (n = 2), leiomyosarcoma (n = 2), chondrosarcoma (n = 2), nephroblastoma (Wilms’s tumor), carcinoid, malignant peripheral nerve sheath tumor, and a gemistiocytic astrocytoma with choroid plexus tumor (each n = 1). Clinical data were collected through a dedicated database and are available for all 40 cases. After a median follow-up of 37 months, 29/40 (72.5%) were alive and disease-free. Stage-specific survival was 100% for stage I, 87.5% for stage II, and 53% for stage III patients suggesting that patients with MSC confined to the testis have a good prognosis. A lower sensitivity to chemotherapy for a MSC when compared with typical GCT is reported. Surgical excision of the MSC is therefore an essential part of the management.

9 March 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MGMarta Giussani
Marta Giussani
ELElena Landoni
Elena Landoni
GMGiuseppe Merlino
Giuseppe Merlino
FTFederica Turdo
Federica Turdo
SVSilvia Veneroni
Silvia Veneroni
Elda TagliabueElda Tagliabue
Elda Tagliabue

24 September 2010 in BJU International
Verified
Journal Article
Closed access
PDF file
Andrea NecchiAndrea Necchi
Andrea Necchi
MCmaurizio VSS colecchia
maurizio VSS colecchia
NNNicola Nicolai
Nicola Nicolai
LPLuigi Piva
Luigi Piva
MCMario Catanzaro
Mario Catanzaro
RSRoberto Salvioni
Roberto Salvioni

27 November 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Tiziana TriulziTiziana Triulzi
Tiziana Triulzi
VRViola Regondi
Viola Regondi
LCLoris De Cecco
Loris De Cecco
MCMaria Rosa Cappelletti
Maria Rosa Cappelletti
MMMartina Di Modica
Martina Di Modica
Elda TagliabueElda Tagliabue
Elda Tagliabue
Background Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab. Methods Gene expression profiles of pre- and post-treatment tumour samples from 17 HER2-positive BC patients were analysed on the Illumina platform. Tumour-associated immune pathways and blood counts were analysed with regard to the response to trastuzumab. HER2-positive murine models with differential responses to trastuzumab were used to reproduce and better characterise these data. Results Patients who responded to single-agent trastuzumab had basal tumour biopsies that were enriched in immune pathways, particularly the MHC-II metagene. One cycle of trastuzumab modulated the expression levels of MHC-II genes, which increased in patients who had a complete response on treatment with trastuzumab and chemotherapy. Trastuzumab increased the MHC-II-positive cell population, primarily macrophages, only in the tumour microenvironment of responsive mice. In patients who benefited from complete trastuzumab therapy and in mice that harboured responsive tumours circulating neutrophil levels declined, but this cell subset rose in nonresponsive tumours. Conclusions Short treatment with trastuzumab induces local and systemic immunomodulation that is associated with clinical outcomes.